Bing Luo

Bing Luo

Auto-generated profile, based on publicly available information

Bing Luo

Phase I Drug Clinical Trial Ward, The First Affiliated Hospital of Sun Yat-sen University, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
BLBing Luo
Bing Luo
ZZZhong-Shan Zhan
Zhong-Shan Zhan
BFBo Fang
Bo Fang
JZJian-Bao Zhang
Jian-Bao Zhang
The construction of 5G system is in the works. In order to improve the anti-interference and reduce the volumes of 5G system, it is important to design a filter with better filtering performance and smaller volume. At present, the research of 5G filter is almost base on metal resonator. This paper designs a ceramic dielectric resonator, and on the basis of the designed dielectric resonator, a 5G band dielectric filter is designed after theoretical calculation and analysis by using rf/microwave simulation software HFSS. The coefficients are realized by the distance between two resonators, and the Q value is realized by the distance between the input port and the first resonator. The results show that in the pass-band (3.4 ∼ 3.5GHz), the return loss is more than 15dB, the insertion loss is less than 0.35dB, and the VSWR is 1.62. The filter has the advantages of small insertion loss, small size and good rejection out of pass-band, which can be applied to 5G band wireless communication system with better suppression performance to improve the communication quality of the communication system.

7 March 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
BLBing Luo
Bing Luo
FYFeng Yu
Feng Yu
WGWeihong Ge
Weihong Ge
XYXian Yang
Xian Yang
Background: Cardiovascular disease is the leading cause of death in most of the world. Previous meta-analyses of generic drugs for the treatment of cardiovascular disease have not provided sufficient evidence to demonstrate the true efficacy and safety of the drugs. Subsequently, concern exists regarding whether the use of generic drugs can fully substitute brand-name drugs in clinical treatment. To enhance the evidence for generic drugs, this meta-analysis compares the actual effectiveness of generic drugs with brand-name drugs in preventing and treating cardiovascular diseases. This study aimed to resolve the controversy over whether generic drugs in cardiovascular disease can replace brand-name drugs, fully evaluating the best evidence on the clinical equivalence of generic drugs. Methods: The PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov databases were searched. The search period included articles published before December 2023. Studies on generic and branded cardiovascular drugs were collected, and two independent reviewers screened eligibility, extracted study data, and assessed the risk of bias. Safety outcomes included major adverse cardiovascular events and other adverse events. Efficacy outcomes included relevant vital signs (e.g., blood pressure, heart rate, urine volume) and laboratory measures (e.g., international normalized ratio, low-density lipoprotein cholesterol, platelet aggregation inhibition). A meta-analysis and subgroup analysis were conducted using the Rev Man software. Results: A total of 4238 studies were retrieved, and 87 studies (n = 2,303,818) were included in the qualitative analysis. There were 57 quantitatively assessed studies (n = 560,553), including angiotensin II receptor blockers, beta-blockers, calcium channel blockers, antithrombotic drugs (anticoagulants or antiplatelet agents), diuretics, statins, and other classes of cardiovascular medications. Regarding clinical safety, 19 studies assessed the occurrence of major adverse cardiovascular events (MACEs) (n = 384,640), and 35 reported secondary adverse events (n = 580,125). In addition to the MACEs for statins (risk ratio (RR) 1.13 [1.05, 1.21]) and adverse events (AEs) for calcium channel blockers (RR 0.90 [0.88, 0.91]), there were no significant differences in the overall risk of MACEs (RR = 1.02 [0.90, 1.15]) and minor adverse events (RR = 0.98 [0.91, 1.05]) between generic and brand-name cardiovascular drugs. In terms of effectiveness, there were no significant differences observed between the two groups in blood pressure (BP), platelet aggregation inhibition (PAI), international normalized ratio (INR), low-density lipoprotein (LDL), and urinary sodium levels. Subgroup analyses for the region, study design, duration of follow-up, and grant funding revealed no significant differences in the risk of MACEs. However, the risk of AE was significantly higher in the Asian region for brand-name cardiovascular drugs than for generics. There was no statistically significant difference in risk between generic and brand-name drugs in the remaining subgroup analyses. Conclusions: Cardiovascular drugs encompass many types; a minority of generic and brand-name drugs have discrepancies. Given the overall development trend of multi-manufacturer generic drugs in the future, this study provides a strong basis for the global application of generic drugs. The feasibility of generic drugs in terms of efficacy and safety in cardiovascular diseases is clarified. However, some drugs still need to be improved to replace the original drugs used in clinical practice completely. Therefore, large-sample, multicenter, high-quality studies are still required to guide the clinical use of cardiovascular drugs. The PROSPERO registration: CRD42023481597, https://www.crd.york.ac.uk/PROSPERO/view/CRD42023481597.

11 September 2025 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
BLBing Luo
Bing Luo
YJYueyun Jiang
Yueyun Jiang
MTMinyi Tan
Minyi Tan
JYJingyan Yang
Jingyan Yang
YFYue Fan
Yue Fan
YCYili Chen
Yili Chen
To systematically evaluate the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K antagonists (VKA) for anticoagulation in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). PubMed, Embase, Web of Science, and the Cochrane Library were searched from their inception through May 2025 to collect relevant clinical studies comparing the use of DOAC versus VKA for the treatment of patients with AF combined with chronic kidney disease. Literature screening, data extraction, analysis, quality evaluation, and risk of bias assessment were conducted by independent reviewers. The outcomes of interest included all-cause mortality, cardiovascular death, stroke or systemic embolism, major bleeding, gastrointestinal bleeding, intracranial bleeding, myocardial infarction, and stroke. Analysis was performed using RevMan 5.4 software, with I2 statistics employed to assess heterogeneity. 16 studies were included in the analysis. Compared with VKA, DOAC can significantly reduced the risks of cardiovascular mortality (HR = 0.78; 95 %CI 0.70-0.87; P < 0.05), major bleeding (HR = 0.79; 95 %CI 0.64-0.97; P < 0.05), and intracranial hemorrhage (HR = 0.50; 95 %CI 0.37-0.66; P < 0.05). No significant differences were observed between the DOAC and VKA groups regarding all-cause death (HR = 0.98; 95 %CI 0.81-1.19; P = 0.82), stroke or systemic embolism (HR = 0.84; 95 %CI 0.68-1.04; P = 0.12), gastrointestinal bleeding (HR = 0.87; 95 %CI 0.61-1.24; P = 0.43), myocardial infarction (HR = 0.98; 95 %CI 0.78-1.23; P = 0.84), or stroke (HR = 0.85; 95 %CI 0.72-1.00; P = 0.06). Overall, DOACs demonstrated superior efficacy in reducing cardiovascular mortality, major bleeding, and intracranial hemorrhage. Among patients with end-stage renal disease, those treated with DOACs showed a tendency toward reduced major bleeding (HR = 0.58; 95 % CI 0.50-0.68; P < 0.05), gastrointestinal hemorrhage (HR = 0.65; 95 %CI 0.48-0.98 P < 0.05), and intracranial hemorrhage (HR = 0.56; 95 % CI, 0.38-0.82; P < 0.05). For patients without end-stage renal disease, the DOAC group had greater benefits in reducing the risks of all-cause death (HR = 0.91; 95 %CI 0.84-0.99; P = 0.03), cardiovascular mortality (HR = 0.77; 95 %CI 0.69-0.86; P < 0.05), major bleeding (HR = 0.85; 95 %CI 0.77-0.83; P < 0.05, and intracranial hemorrhage (HR = 0.42; 95 % CI, 0.28-0.65; P < 0.05). Conversely, the VKA group was more effective in reducing the risk of gastrointestinal hemorrhage events (HR = 1.38; 95 % CI 1.13-1.68; P < 0.05). In patients with non-valvular AF complicated by CKD, the use of DOAC is associated with a moderate reduction in the risks of cardiovascular mortality, major bleeding, and intracranial hemorrhage. Among patients with end-stage renal disease, DOACs offer more significant benefits in reducing the risks of major bleeding, gastrointestinal hemorrhage, and intracranial hemorrhage. For patients with non-end-stage renal disease, DOAC are associated with lower rates of all-cause death, cardiovascular mortality, major bleeding, and intracranial hemorrhage, whereas VKA are linked to an increased risk of gastrointestinal hemorrhage.

1 August 2021 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
PDF file
BLBing Luo
Bing Luo
ZZZhong-Shan Zhan
Zhong-Shan Zhan
BFBo Fang
Bo Fang
YZYongliang Zhang
Yongliang Zhang
Based on 5G system, a cylindrical dual-mode resonator and filter are designed. The electric field distribution characteristics of each mode of the dual-mode resonator are analyzed by using high-frequency electromagnetic field simulation software. Based on the designed dual-mode resonator, through theoretical calculation and analysis, a 5G system dielectric dual-mode filter is designed by using the RF / microwave simulation software ADS/HFSS. The coupling between modes is realized by setting metal screw perturbation on surfaces. The effect of two coupled degenerate modes is equivalent to that of two coupled resonators, so that the number of resonators can be reduced while the resonant circuit remains unchanged. For example, two modes of a resonator can be used in a traditional n-section filter, the same physical space realizes the characteristic of 2n section filter, which greatly reduces the size of the filter. A 5G system dielectric filter is designed based on dual-mode resonator. The results show that in the pass-band (3.4 ∼ 3.5GHz), the return loss is more than 18db, the insertion loss is less than 0.3dB, the zero on the left side of the pass-band is 3.1716GHz, the zero on the right side of the pass-band is 3.8537GHz, the VSWR is less than 1.28. Transmission zeros are introduced on both sides of the pass-band, which improves the suppression ability out of pass-band. The 5G system dielectric filter has the advantages of low insertion loss, small size and good suppression performance out of pass-band. When applied to 5G wireless communication system, the anti-interference ability and stability of the system can be improved.

12 November 2021
Verified
Conference Paper
Closed access
BLBing Luo
Bing Luo
QLQian-Qian Li
Qian-Qian Li
JZJian-Bao Zhang
Jian-Bao Zhang
HYHuiqi Yang
Huiqi Yang
A 5G band dielectric filter with symmetrical zero is designed in this paper. The metal cylinder is used to change the electric field distribution of the mode, then the mutual coupling between the modes is realized. The effect of two coupled degenerate modes is equivalent to two coupled resonators, so one dual-mode resonator can realize the filtering characteristics of two single-mode resonators. The 5G band dielectric filter of China Telecom is designed by using single cavity and dual-mode, and two transmission zeros are realized on both sides of the passband to improve the out-band suppression ability. The results show that in the pass-band (3.4 ~ 3.5 GHz), the return loss is larger than 16.8 dB, the insertion loss is less than 0.35 dB, the zero point on the left side of the pass-band is 3.182 GHz, the zero point on the right side of the pass-band is 3.842 GHz, and the standing wave ratio is less than 1.27. All results prove its excellent performance and can be applied to 5G systems well.